Sidley Austin advised Healthcare Royalty on the deal. HealthCare Royalty, a leading royalty acquisition company, announced its US$250 million non-dilutive note purchase agreement with OPKO Health,...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Biolojic Design, Ltd. in the deal. Biolojic Design, Ltd. (Biolojic), a biotechnology company, announced it has entered into a multi-target drug discovery collaboration...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Carlin Consumer Health in the transaction, and Jones Day represented American Pacific Group. Carlin Consumer Health (“Carlin”) announced its acquisition of PENETREX® (“Penetrex”)...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented BigHat Biosciences in the transaction. BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced its collaboration...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Pyxis Oncology, Inc. on the deal. Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company, announced that it agreed to sell 8,849,371 shares of...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Sagard Healthcare in the transaction, and Cooley represented MannKind Corporation. Sagard Healthcare (Sagard) announced it entered into a royalty purchase agreement, under which...
You must be a Standard 1 Year member to access this content.
Sidley Austin represented Praxis Precision Medicines, Inc. in the transaction, and Ropes & Gray advised Tenacia. Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced it has entered...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP served as legal advisor to Carlin and Wilson Sonsini Goodrich Rosati acted as legal advisor to Infirst. Stifel acted as exclusive financial advisor...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
You must be a Standard 1 Year member to access this content.
Sidley advised Akeso Inc. on the deal. Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Yisheng Biopharma Co., Ltd. on the deal, while Sidley Austin LLP and Maples and Calder advised R-Bridge Healthcare Fund. Yisheng Biopharma Co.,...
You must be a Standard 1 Year member to access this content.
